A genetic advance: lipoprotein(a) in aortic stenosis

References

• Thanassoulis G, Campbell CY, Owens DS et al. Genetic associations with valvular calcification and aortic stenosis. N. Engl. J. Med. 368, 503–512 (2013).
   Google Scholar
• Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518–2528 (2009).
   Google Scholar
• Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr. Opin. Lipidol. 10, 133–141 (1991).
   Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844–2853 (2010).
   Google Scholar
• Bostom AG, Gagnon DR, Cupples LA et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation 90, 1688–1695 (1994).
   Google Scholar
• Bozbas H, Yildirir A, Atar I et al. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J. Heart Valve Dis. 16, 387–393 (2007).
   Google Scholar
• Gotoh T, Kuroda T, Yamasawa M et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am. J. Cardiol. 76, 928–932 (1995).
   Google Scholar
• Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease: cardiovascular health study. J. Am. Coll. Cardiol. 29, 630–634 (1997).
   Google Scholar
• Généreux P, Head SJ, Wood DA et al. Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. Eur. Heart J. 33, 2388–2398 (2012).
   Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331–2339 (2009).
   Google Scholar
• Tregouet DA, Konig IR, Erdmann J et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41, 283–285 (2009).
   Google Scholar
• Malaguarnera M, Vacante M, Russo C et al. Liproprotein(a) in cardiovascular diseases. Biomed. Res. Int. 2013, 650989 (2013).
   Google Scholar
• Ghaisas NK, Foley JB, O’Briain DS, Crean P, Kelleher D, Walsh M. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J. Am. Coll. Cardiol. 36, 2257–2262 (2000).
   Google Scholar
• O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler. Thromb. Vasc. Biol. 16, 523–532 (1996).
   Google Scholar
• Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler.Thromb. Vasc. Biol. 19, 1218–1222 (1999).
   Google Scholar
• Jian B, Narula N, Li QY, Mohler ER 3rd, Levy RJ. Progression of aortic valve stenosis: TGF-b1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann. Thorac. Surg. 75, 457–465 (2003).
   Google Scholar
• Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 171, 1407–1418 (2007).
   Google Scholar
• Garg V, Muth AN, Ransom JF et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270–274 (2005).
   Google Scholar
• Yanagawa B, Lovren F, Pan Y et al. miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. J. Thorac. Cardiovasc. Surg. 144, 256–262 (2012).
   Google Scholar
• Cowell SJ, Newby DE, Prescott RJ et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352, 2389–2397 (2005).
   Google Scholar
• Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Rffects of Rosuvastatin (ASTRONOMER) trial. Circulation 121, 306–314 (2010).
   Google Scholar
• Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80, 1313–1319 (1989).
   Google Scholar
• Yoshida H, Shoda T, Yanai H et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis 226, 161–164 (2013).
   Google Scholar
• Deshmukh HA, Colhoun HM, Johnson T et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J. Lipid Res. 53, 1000–1011 (2012).
   Google Scholar